Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VRNA 
Verona Pharma PLC ADR (VRNA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: VRNA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 1223.32% | Avg. Invested days 76 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.54B USD | Price to earnings Ratio - | 1Y Target Price 81 |
Price to earnings Ratio - | 1Y Target Price 81 | ||
Volume (30-day avg) 1362833 | Beta 0.39 | 52 Weeks Range 11.39 - 70.40 | Updated Date 03/27/2025 |
52 Weeks Range 11.39 - 70.40 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-02-27 | When - | Estimate -0.15 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) -48.51% |
Management Effectiveness
Return on Assets (TTM) -24.13% | Return on Equity (TTM) -76.42% |
Valuation
Trailing PE - | Forward PE 416.67 | Enterprise Value 5179406722 | Price to Sales(TTM) 202.06 |
Enterprise Value 5179406722 | Price to Sales(TTM) 202.06 | ||
Enterprise Value to Revenue 122.51 | Enterprise Value to EBITDA -20.89 | Shares Outstanding 85018096 | Shares Floating 492986283 |
Shares Outstanding 85018096 | Shares Floating 492986283 | ||
Percent Insiders 6.04 | Percent Institutions 85.2 |
Analyst Ratings
Rating 4.62 | Target Price 61 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Verona Pharma PLC ADR
Company Overview
History and Background
Verona Pharma PLC is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Founded in 2006, the company has evolved from early-stage research to late-stage clinical development, with a primary focus on COPD.
Core Business Areas
- Respiratory Therapeutics: Developing and commercializing therapies for respiratory diseases, primarily focusing on COPD, asthma and viral induced respiratory disease. The company's lead product is ensifentrine.
Leadership and Structure
David Zaccardelli serves as the CEO and President. The company has a Board of Directors responsible for overall governance. The organizational structure is typical of a biopharmaceutical company, with departments for R&D, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Ensifentrine: Ensifentrine is a first-in-class, inhaled, dual PDE3 and PDE4 inhibitor being developed for the treatment of respiratory diseases, including COPD. Market share is currently 0% as the drug is awaiting regulatory approval. Competitors include inhaled corticosteroids, long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs), and triple therapies for COPD (e.g., Trelegy Ellipta from GSK).
Market Dynamics
Industry Overview
The respiratory therapeutics market is large and growing, driven by increasing prevalence of respiratory diseases such as COPD and asthma. The market is characterized by intense competition and innovation.
Positioning
Verona Pharma is positioned as an innovator with its novel dual PDE3 and PDE4 inhibitor, ensifentrine, aiming to address unmet needs in COPD and other respiratory diseases. Competitive advantages may stem from the drug's novel mechanism of action and potential for improved efficacy and safety compared to existing therapies.
Total Addressable Market (TAM)
The global COPD market is estimated to be worth over $15 billion. Verona Pharma is targeting a portion of this market with ensifentrine, aiming to become a significant player in the respiratory therapeutics space.
Upturn SWOT Analysis
Strengths
- Novel dual PDE3 and PDE4 inhibitor mechanism
- Positive Phase 3 clinical trial results for ensifentrine
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Dependence on a single lead product (ensifentrine)
- Lack of commercialization infrastructure
- Limited financial resources compared to larger pharmaceutical companies
- Risk of regulatory approval delays or rejection
Opportunities
- Potential for ensifentrine to become a blockbuster drug for COPD
- Expansion into other respiratory diseases such as asthma
- Partnerships with larger pharmaceutical companies for commercialization
- Favorable regulatory environment for innovative therapies
Threats
- Competition from existing COPD therapies
- Emergence of new COPD therapies
- Pricing pressures from healthcare payers
- Clinical trial failures or safety concerns
Competitors and Market Share
Key Competitors
- GSK (GSK)
- AstraZeneca (AZN)
- Boehringer Ingelheim (No US Stock Symbol)
Competitive Landscape
Verona Pharma faces intense competition from established pharmaceutical companies with existing COPD therapies. However, Verona Pharma's novel mechanism of action and potential for improved efficacy and safety may provide a competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Verona Pharma has historically been focused on R&D, with limited revenue generation. Growth is expected to accelerate upon potential commercialization of ensifentrine.
Future Projections: Analyst estimates project significant revenue growth for Verona Pharma in the coming years, driven by ensifentrine sales. Profitability is expected to improve as sales ramp up.
Recent Initiatives: Recent strategic initiatives include completion of Phase 3 clinical trials for ensifentrine, preparation for regulatory submissions, and building a commercialization infrastructure.
Summary
Verona Pharma is a biopharmaceutical company poised for potential growth with its lead product, ensifentrine, aimed at the COPD market. Positive clinical trial results and upcoming regulatory submissions position the company well. However, the company faces strong competition from established players and the inherent risks associated with drug development. Success hinges on successful commercialization of ensifentrine and expanding its pipeline.
Similar Companies
- GSK
- AZN
- HLX
Sources and Disclaimers
Data Sources:
- Verona Pharma PLC's website
- SEC filings
- Analyst reports
- Company press releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share information is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verona Pharma PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-04-27 | President, CEO & Executive Director Dr. David S. Zaccardelli Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.veronapharma.com |
Full time employees 209 | Website https://www.veronapharma.com | ||
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.